Swine Flu Could Boost GlaxoSmithKline

July 21, 2009 by srrpenna

From Forbes

The new flu strain can be treated by antivirals such as GlaxoSmithKline's Relenza, which may provide with up to 350 million pounds ($573 million) in sales, according to some estimates. The company is also expected to benefit from its vaccine treatment against the H1N1 virus by posting up to 1.3 billion pounds ($2.1 billion) in sales in 2010. But industry experts warn it won't be able to extrapolate these numbers for many years as a swine flu pandemic is likely to result in one-off gains.

Permalink